Keywords: Biogen Idec, Swedish Orphan Biovitrum, Hemophilia, Registrational trial
Biogen Idec and Swedish Orphan Biovitrum advance long-lasting hemophilia A therapy into registrational trial
Article | 12 July 2010
US biotech firm Biogen Idec and Stockholm-based Swedish Orphan Biovitrum (SOBI) say they plan to advance the companies' long-lasting, fully-recombinant ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
